Brief: Lee's Pharmaceutical Holdings Says Idmc Recommends Discontinuation Of Trial For Liver Cancer Treatment
05/08/2019 02:25
Aug 5 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* IDMC RECOMMENDED DISCONTINUATION OF PHASE 3 CLINICAL TRIAL
FOR
ONCOLYTIC IMMUNOTHERAPY FOR ADVANCED LIVER CANCER
* INTERIM RESULTS OF TREATMENT SUGGEST THAT THE STUDY IS
UNLIKELY
TO MEET PRIMARY OBJECTIVE
Source text for Eikon: urn:newsml:reuters.com:*:nHKS7TZBHf
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lees Pharmaceutical Holdings
See all newsBrief: Lee's Pharmaceutical Announces Share Repurchase Program Under Repurchase Mandate
Brief: Lee's Pharmaceutical To Receive Funding From Gates Foundation For Synthetic Surfactant Project
Brief: Lee's Pharmaceutical Says Zhaoke Hefei To Contribute Rmb25 Million To Partnership Fund
Brief: Lee's Pharmaceutical Declares Final Dividend Of HK2.3 Cents Per Share
Brief: Lee's Pharmaceutical Reports Approval Of Intrarosa By NMPA